Objective: Sjögren syndrome (SS) is an autoimmune disease involving exocrine glands. Currently, drugs that can improve both abnormal immunity and exocrine gland function are needed. The study aimed to investigate the effect and mechanism of vasoactive intestinal peptide (VIP) on the immune response and exocrine gland function in SS. Methods: We investigated the effects of VIP on the immune response and secretory function of submandibular glands using NOD mice, and analyzed the expression of IL-17A and AQP5 (aquaporin 5). The submandibular gland cells from healthy 8-day-old Sprague-Dawley rats were used to observe the influence of VIP on AQP5 expression. Results: Our study shows that treatment with VIP in an SS mouse model could not only reduce the immune injury to exocrine glands but also improve the secretory function of these glands. Furthermore, VIP was shown to improve the abnormal immune status by downregulating IL-17A expression in the exocrine glands. It also enhanced the secretory function of exocrine glands by upregulating AQP5 expression. Conclusions: Using a model of SS, we found that VIP could not only modulate the immune response but also affect exocrine gland function, and that these therapeutic effects were associated with IL-17A and AQP5 regulation.

Keywords:
Sjögren syndrome, Vasoactive intestinal peptide, IL-17A, AQP5
1.
Nocturne G, Mariette X: Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol 2013; 9: 544–556.
2.
Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA: Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford) 2006; 45: 187–191.
3.
Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR: Estimating the prevalence among Caucasian women of primary Sjögren’s syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004; 33: 39–43.
4.
Tomsic M, Logar D, Grmek M, Perkovic T, Kveder T: Prevalence of Sjögren’s syndrome in Slovenia. Rheumatology (Oxford) 1999; 38: 164–170.
5.
Both T, Dalm VA, van Hagen PM, van Daele PL: Reviewing primary Sjögren’s syndrome: beyond the dryness – from pathophysiology to diagnosis and treatment. Int J Med Sci 2017; 14: 191–200.
6.
Mieliauskaite D, Dumalakiene I, Rugiene R, Mackiewicz Z: Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren’s syndrome. Clin Dev Immunol 2012; 2012: 187258.
7.
Dawson LJ, Fox PC, Smith PM: Sjögrens syndrome – the non-apoptotic model of glan-dular hypofunction. Rheumatology (Oxford) 2006; 45: 792–798.
8.
Fox RI, Maruyama T: Pathogenesis and treatment of Sjögren’s syndrome. Curr Opin Rheumatol 1997; 9: 393–399.
9.
Hayashi T: Dysfunction of lacrimal and salivary glands in Sjögren’s syndrome: nonimmunologic injury in preinflammatory phase and mouse model. J Biomed Biotechnol 2011; 2011: 407031.
10.
Luo Q, Wang Y, Feng D, Xu Y, Xu L: Vasoactive intestinal peptide attenuates concanava-lin A-mediated liver injury. Eur J Pharmacol 2009; 607: 226–233.
11.
Rhodus NL: Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren’s syndrome. Oral Dis 1997; 3: 93–98.
12.
Alam J, Koh JH, Kwok SK, Park SH, Park K, Choi Y: Functional epitopes for anti-aquaporin 5 antibodies in Sjögren syndrome. J Dent Res 2017; 96: 1414–1421.
13.
Ma T, Song Y, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS: Defective secretion of saliva in transgenic mice lacking aquaporin-5 wa ter channels. J Biol Chem 1999; 274: 20071–20074.
14.
Bik W, Wolinska-Witort E, Chmielowska M, Baranowska-Bik A, Rusiecka-Kuczalek E, Baranowska B: Vasoactive intestinal peptide can modulate immune and endocrine responses during lipopolysaccharide-induced acute inflammation. Neuroimmunomodulation 2004; 11: 358–364.
15.
Foster N: Editorial: vasoactive intestinal peptide (VIP): historic perspective and future potential. Endocr Metab Immune Disord Drug Targets 2012; 12: 303–307.
16.
Hauk V, Calafat M, Larocca L, Fraccaroli L, Grasso E, Ramhorst R, Leirós CP: Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjö gren’s syndrome. Clin Exp Immunol 2011; 166: 309–316.
17.
Törnwall J, Konttinen YT, Hietanen J, Sorsa T, Hukkanen M, Uusitalo H: VIP in salivary glands in Sjögren’s syndrome. Br J Rheumatol 1995; 34: 891–893.
18.
Ma L, Huang YG, He H, Deng YC, Zhang HF, Che HL, Tian JY, Zhao G: Postnatal expression and denervation induced up-regulation of aquaporin-5 protein in rat sweat gland. Cell Tissue Res 2007; 329: 25–33.
19.
Chisholm DM, Mason DK: Labial salivary gland biopsy in Sjögren’s disease. J Clin Pathol 1968; 21: 656–660.
20.
Zhang LW, Cong X, Zhang Y, Wei T, Su YC, Serrao AC, Brito AJ, Yu GY, Hua H, Wu LL: Interleukin-17 impairs salivary tight junction integrity in Sjögren’s syndrome. J Dent Res 2016; 95: 784–792.
21.
Yamano S, Atkinson JC, Baum BJ, Fox PC: Salivary gland cytokine expression in NOD and normal BALB/c mice. Clin Immunol 1999; 92: 265–275.
22.
Lai Z, Yin H, Cabrera-Pérez J, Guimaro MC, Afione S, Michael DG, Glenton P, Patel A, Swaim WD, Zheng C, Nguyen CQ, Nyberg F, Chiorini JA: Aquaporin gene therapy corrects Sjögren’s syndrome phenotype in mice. Proc Natl Acad Sci USA 2016; 113: 5694–5699.
23.
Itoh A, Tsujikawa T, Fujiyama Y, Bamba T: Enhancement of aquaporin-3 by vasoactive intestinal polypeptide in a human colonic epithelial cell line. J Gastroenterol Hepatol 2003; 18: 203–210.
24.
Tsujikawa T, Itoh A, Fukunaga T, Satoh J, Yasuoka T, Fujiyama Y: Alteration of aquaporin mRNA expression after small bowel resection in the rat residual ileum and colon. J Gastroenterol Hepatol 2003; 18: 803–808.
25.
Soyfoo MS, Steinfeld S, Delporte C: Usefulness of mouse models to study the pathogenesis of Sjögren’s syndrome. Oral Dis 2007; 13: 366–375.
26.
Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM: Systemic and local interleukin-17 and linked cytokines associated with Sjögren’s syndrome immunopathogenesis. Am J Pathol 2009; 175: 1167–1177.
27.
Voigt A, Esfandiary L, Wanchoo A, Glenton P, Donate A, Craft WF, Craft SL, Nguyen CQ: Sexual dimorphic function of IL-17 in salivary gland dysfunction of the C57BL/6.NOD- Aec1Aec2 model of Sjögren’s syndrome. Sci Rep 2016; 6: 38717.
28.
Parvin MN, Kurabuchi S, Murdiastuti K, Yao C, Kosugi-Tanaka C, Akamatsu T, Kanamori N, Hosoi K: Subcellular redistribution of AQP5 by vasoactive intestinal polypeptide in the Brunner’s gland of the rat duodenum. Am J Physiol Gastrointest Liver Physiol 2005; 288:G1283–G1291.
29.
Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP, Baum BJ: Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren’s syndrome. Ann Rheum Dis 2006; 65: 195–200.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.